Cite
HARVARD Citation
Lapointe, R. et al. (2015). Immune biomarker correlates from a Phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM). Journal for immunotherapy of cancer. 3 (2), p. 1. [Online].